Preparing pharma for end of Brexit transition: ABPI response
The Department of Health and Social Care has published a letter setting out the Government’s plan and requests of industry and the wider supply chain...
Orphan Drug Designation granted to tinostamustine in EU for very rare form of leukaemia
Mundipharma has announced that the European Commission (EC) has now adopted the European Medicines Agency (EMA) Committee for Orphan Medicinal Products recommendation to grant...
Novartis Cosentyx® receives EU approval for first-line systemic treatment in paediatric psoriasis
Novartis has announced that Cosentyx® has received EU approval for first-line systemic treatment in paediatric psoriasis. The European Commission (EC) has granted the approval for...
Empagliflozin (Jardiance®) meets primary endpoint in Phase III heart failure trial
Positive top-line results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction (HFrEF), with and without type 2...
GSK & Sanofi strike deal to supply UK with up to 60m doses of...
Sanofi and GSK have reached an agreement* with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine. Developed...
High-risk groups should have priority for COVID-19 vaccine – poll
The biopharmaceutical industry believes that high-risk groups should be prioritised for the COVID-19 vaccine, according to a poll by GlobalData. Nearly half of global respondents...
AMBAR clinical trial results published in Journal of the Alzheimer’s Association
Peer-reviewed scientific journal, Alzheimer’s & Dementia: The Journal of the Alzheimer's Association, has published the results of Grifols’ AMBAR clinical trial. This study was...
AstraZeneca’s Imfinzi recommended for approval in the EU
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adults with extensive-stage small cell...
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
Novartis has launched a first-of-its-kind not-for-profit portfolio of medicines for the symptomatic treatment of COVID-19. Novartis has announced a new initiative to help patients in...
Oxford coronavirus vaccine produces strong immune response
A new study has revealed that the Oxford coronavirus vaccine produces a strong immune response. The results of the Phase I/II trial published in the...
Latest articles
AI-driven chemistry retrosynthesis tool to advance drug discovery
In a bid to help to bring drugs to market for patients most in need, Elsevier, a global research publishing and information analytics provider,...
Lifting the lid on robotic process automation
Today, robotic process automation (RPA) registers strongly on the radar of Regulatory Affairs departments; many companies are talking about it or looking at it,...
Healthcare service providers Star Medical and OUTiCO merge to create new brand identity
Star OUTiCO, a market-leading provider of outsourced digitally enabled commercial services to the pharmaceutical industry and part of the global Uniphar Group, has launched...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Rapid COVID-19 diagnostic test to be deployed in hospitals
A new rapid COVID-19 diagnostic test developed by a University of Cambridge spinout company and capable of diagnosing the infection in under 90 minutes,...
Healthcare service providers Star Medical and OUTiCO merge to create new brand identity
Star OUTiCO, a market-leading provider of outsourced digitally enabled commercial services to the pharmaceutical industry and part of the global Uniphar Group, has launched...
AI-driven chemistry retrosynthesis tool to advance drug discovery
In a bid to help to bring drugs to market for patients most in need, Elsevier, a global research publishing and information analytics provider,...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...